Heterologous production of ribostamycin derivatives in engineered Escherichia coli

Nagendra Prasad Kurumbang, Je Won Park, Yeo Joon Yoon, Kwangkyoung Liou, Jae Kyung Sohng

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aminoglycosides are a class of important antibiotic compounds used for various therapeutic indications. In recent times, their efficacy has been curtailed due to the rapid development of bacterial resistance. There is a need to develop novel derivatives with an improved spectrum of activity and higher sensitivity against pathogenic bacteria. Although efforts have been focused on the development of newer therapeutic agents by chemical synthesis, to our knowledge, there has been no attempt to harness the potential of microorganisms for this purpose. Escherichia coli affords a widely studied cellular system that could be utilized not only for understanding but also for attempting to engineer the biosynthetic pathway of secondary metabolites. The primary metabolic pathway of E. coli can be engineered to divert the precursor pool required for the biosynthesis of secondary metabolites. Utilizing this approach previously, we engineered E. coli host and generated E. coli M1. Here, we produced a ribostamycin derivative in the engineered host by heterologous expression of the recombinants constructed from the genes encoding the biosynthetic pathway in aminoglycoside-producing strains. The products obtained from the transformants were isolated, analyzed and verified to be ribostamycin derivatives. The study further demonstrated the importance of E. coli as surrogate antibiotic producer and also offered future possibility for the production of other aminoglycoside derivatives through genetic engineering and expression in a heterologous background.

Original languageEnglish
Pages (from-to)526-533
Number of pages8
JournalResearch in Microbiology
Volume161
Issue number7
DOIs
Publication statusPublished - 2010 Sep 1
Externally publishedYes

Fingerprint

Ribostamycin
Escherichia coli
Aminoglycosides
Biosynthetic Pathways
Anti-Bacterial Agents
Genetic Engineering
Metabolic Networks and Pathways
Bacteria
Therapeutics
Genes

Keywords

  • 2-Deoxystreptamine
  • Aminoglycosides
  • Co-expression
  • Eengineered Escherichia coli
  • Heterologous production

ASJC Scopus subject areas

  • Microbiology
  • Molecular Biology

Cite this

Heterologous production of ribostamycin derivatives in engineered Escherichia coli. / Kurumbang, Nagendra Prasad; Park, Je Won; Yoon, Yeo Joon; Liou, Kwangkyoung; Sohng, Jae Kyung.

In: Research in Microbiology, Vol. 161, No. 7, 01.09.2010, p. 526-533.

Research output: Contribution to journalArticle

Kurumbang, Nagendra Prasad ; Park, Je Won ; Yoon, Yeo Joon ; Liou, Kwangkyoung ; Sohng, Jae Kyung. / Heterologous production of ribostamycin derivatives in engineered Escherichia coli. In: Research in Microbiology. 2010 ; Vol. 161, No. 7. pp. 526-533.
@article{b86a34047e10487a81a01444909bb724,
title = "Heterologous production of ribostamycin derivatives in engineered Escherichia coli",
abstract = "Aminoglycosides are a class of important antibiotic compounds used for various therapeutic indications. In recent times, their efficacy has been curtailed due to the rapid development of bacterial resistance. There is a need to develop novel derivatives with an improved spectrum of activity and higher sensitivity against pathogenic bacteria. Although efforts have been focused on the development of newer therapeutic agents by chemical synthesis, to our knowledge, there has been no attempt to harness the potential of microorganisms for this purpose. Escherichia coli affords a widely studied cellular system that could be utilized not only for understanding but also for attempting to engineer the biosynthetic pathway of secondary metabolites. The primary metabolic pathway of E. coli can be engineered to divert the precursor pool required for the biosynthesis of secondary metabolites. Utilizing this approach previously, we engineered E. coli host and generated E. coli M1. Here, we produced a ribostamycin derivative in the engineered host by heterologous expression of the recombinants constructed from the genes encoding the biosynthetic pathway in aminoglycoside-producing strains. The products obtained from the transformants were isolated, analyzed and verified to be ribostamycin derivatives. The study further demonstrated the importance of E. coli as surrogate antibiotic producer and also offered future possibility for the production of other aminoglycoside derivatives through genetic engineering and expression in a heterologous background.",
keywords = "2-Deoxystreptamine, Aminoglycosides, Co-expression, Eengineered Escherichia coli, Heterologous production",
author = "Kurumbang, {Nagendra Prasad} and Park, {Je Won} and Yoon, {Yeo Joon} and Kwangkyoung Liou and Sohng, {Jae Kyung}",
year = "2010",
month = "9",
day = "1",
doi = "10.1016/j.resmic.2010.04.013",
language = "English",
volume = "161",
pages = "526--533",
journal = "Research in Microbiology",
issn = "0923-2508",
publisher = "Elsevier Masson SAS",
number = "7",

}

TY - JOUR

T1 - Heterologous production of ribostamycin derivatives in engineered Escherichia coli

AU - Kurumbang, Nagendra Prasad

AU - Park, Je Won

AU - Yoon, Yeo Joon

AU - Liou, Kwangkyoung

AU - Sohng, Jae Kyung

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Aminoglycosides are a class of important antibiotic compounds used for various therapeutic indications. In recent times, their efficacy has been curtailed due to the rapid development of bacterial resistance. There is a need to develop novel derivatives with an improved spectrum of activity and higher sensitivity against pathogenic bacteria. Although efforts have been focused on the development of newer therapeutic agents by chemical synthesis, to our knowledge, there has been no attempt to harness the potential of microorganisms for this purpose. Escherichia coli affords a widely studied cellular system that could be utilized not only for understanding but also for attempting to engineer the biosynthetic pathway of secondary metabolites. The primary metabolic pathway of E. coli can be engineered to divert the precursor pool required for the biosynthesis of secondary metabolites. Utilizing this approach previously, we engineered E. coli host and generated E. coli M1. Here, we produced a ribostamycin derivative in the engineered host by heterologous expression of the recombinants constructed from the genes encoding the biosynthetic pathway in aminoglycoside-producing strains. The products obtained from the transformants were isolated, analyzed and verified to be ribostamycin derivatives. The study further demonstrated the importance of E. coli as surrogate antibiotic producer and also offered future possibility for the production of other aminoglycoside derivatives through genetic engineering and expression in a heterologous background.

AB - Aminoglycosides are a class of important antibiotic compounds used for various therapeutic indications. In recent times, their efficacy has been curtailed due to the rapid development of bacterial resistance. There is a need to develop novel derivatives with an improved spectrum of activity and higher sensitivity against pathogenic bacteria. Although efforts have been focused on the development of newer therapeutic agents by chemical synthesis, to our knowledge, there has been no attempt to harness the potential of microorganisms for this purpose. Escherichia coli affords a widely studied cellular system that could be utilized not only for understanding but also for attempting to engineer the biosynthetic pathway of secondary metabolites. The primary metabolic pathway of E. coli can be engineered to divert the precursor pool required for the biosynthesis of secondary metabolites. Utilizing this approach previously, we engineered E. coli host and generated E. coli M1. Here, we produced a ribostamycin derivative in the engineered host by heterologous expression of the recombinants constructed from the genes encoding the biosynthetic pathway in aminoglycoside-producing strains. The products obtained from the transformants were isolated, analyzed and verified to be ribostamycin derivatives. The study further demonstrated the importance of E. coli as surrogate antibiotic producer and also offered future possibility for the production of other aminoglycoside derivatives through genetic engineering and expression in a heterologous background.

KW - 2-Deoxystreptamine

KW - Aminoglycosides

KW - Co-expression

KW - Eengineered Escherichia coli

KW - Heterologous production

UR - http://www.scopus.com/inward/record.url?scp=77956281445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956281445&partnerID=8YFLogxK

U2 - 10.1016/j.resmic.2010.04.013

DO - 10.1016/j.resmic.2010.04.013

M3 - Article

VL - 161

SP - 526

EP - 533

JO - Research in Microbiology

JF - Research in Microbiology

SN - 0923-2508

IS - 7

ER -